UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2018 (June 16, 2018)
LUCKWEL PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-187874 | 46-1660653 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| One International Place, Suite 1400, Boston | MA 02110 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, include area code +1(617) 335 7788
11757 Katy Freeway, Suite 1300-A, Houston, Texas 77079 .
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.01 Entry into a Material Definitive Agreement
On June 16, 2018, Luckwel Pharmaceuticals Inc. (the “Company”) entered into a virtual office service agreement with Servcorp Limited (the “Agreement”), pursuant to which the Company leased an office space located at Suite 1400, Boston, MA 02110. The lease under the Agreement started on June 16, 2018 and is on a month to month basis for which the Company pays a monthly rent of $299.
This description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits |
| 10.1 | Virtual Office Service Agreement dated June 16, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LUCKWEL PHARMACEUTICALS INC. | |||
| Date: | June 20, 2018 | /s/ Kingrich Lee | |
| Name: | Kingrich Lee | ||
| Title: | Chief Executive Officer and Chief Financial Officer | ||